Sangamo Therapeutics Inc.

Sangamo Therapeutics Inc.

IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Mucopolysaccharidosis I, MPS I, (2018-000206-28)
Sponsors:
Sangamo Therapeutics, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Haemophilia B Factor IX, (2017-004805-42)
Sponsors:
Sangamo Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT03653247)
Sponsors:
Sangamo Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Mucopolysaccharidosis II, MPS II, (NCT03041324)
Sponsors:
Sangamo Therapeutics Inc. 
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine